The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
Published in MedTech Strategist
Authors: Wendy Diller, Oded Ben-Joseph, Craig Steger, and Thomas Joyce
Abstract:
The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
Blockbuster drug patent expiration, advances in enabling technology, and the emergence of personalized medicine for prostate cancer treatment create a landscape worth examining.
DownloadOutcome Capital Life Science Market Pulse March 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?